People: AtriCure Inc (ATRC.W)

ATRC.W on CBOE When Trading NASDAQ Global Select Market

9.10USD
17 May 2013
Price Change (% chg)

$-0.03 (-0.33%)
Prev Close
$9.13
Open
$9.10
Day's High
$9.10
Day's Low
$9.10
Volume
100
Avg. Vol
240
52-wk High
$9.65
52-wk Low
$5.99

Search Stocks

Summary

Name Age Since Current Position

Richard Johnston

 77 2005 Independent Chairman of the Board

Michael Carrel

 42 2012 President, Chief Executive Officer, Director

M. Andrew Wade

 37 2012 Principal Financial Officer, Principal Accounting Officer

Andrew Lux

 60 2012 Chief Operating Officer, Vice President

Patricia Kennedy

 51 2011 Vice President, General Manager - International

Michael Rogge

 2013 Vice President - Marketing

Stewart Strong

 45 2011 Vice President - Global Marketing

James Lucky

 50 2012 Vice President - Regulatory Affairs and Quality Systems

Michael Hooven

 56 2007 Director

Mark Collar

 59 2008 Independent Director

Donald Harrison

 2000 Independent Director

Elizabeth Krell

 63 2006 Independent Director

Mark Lanning

 57 2006 Independent Director

Karen Robards

 63 2000 Independent Director

Robert White

 2013 Independent Director
» Insider Trading

Biographies

Name Description

Richard Johnston

 Mr. Richard M. Johnston is Independent Chairman of the Board of AtriCure Inc. He has served as one of directors since June 2002 and as Chairman of the Board since February 2005. From 2000 to 2010, Mr. Johnston served as a Managing Member of Camden Partners Holdings, LLC, a private equity firm, and he is now a Retired Member of that firm. Mr. Johnston currently serves as a director of BioMedical Enterprises, Inc., Lombard Medical Technologies PLC, Medivance, Inc. and Webmedx, Inc., all Camden Partners’ portfolio companies of which Lombard Medical Technologies PLC is a publicly-held company in the United Kingdom. During the last five years Mr. Johnston previously served as director of privately-held LipoScience Inc. and as Chairman of privately-held Picis, Inc. as well as a director of Pet DRx Corporation, a publicly-held company. From 1961 to 2000, Mr. Johnston was employed by The Hillman Company, an investment holding company with diversified operations, where he served from 1970 to 2000 as Vice President, Investments and as a director. From 1979 to 2003, Mr. Johnston was Chairman of the Board of The Western Pennsylvania Hospital and its successors, The Western Pennsylvania Healthcare System and West Penn Allegheny Health System. Mr. Johnston received his B.S. from Washington and Lee University and his M.B.A. from The Wharton School, University of Pennsylvania.

Michael Carrel

 Mr. Michael H. Carrel is appointed as the President, Chief Executive Officer, Director of AtriCure Inc. Prior to joining AtriCure, Mr. Carrel was the President and Chief Executive Officer of Vital Images (Nasdaq: VTAL) from 2008 until it was sold to Toshiba in 2011; he stayed on as Chief Executive Officer of the new business unit within Toshiba until 2012. He originally joined Vital Images in January of 2005 as Chief Operating and Financial Officer. During his time at Vital, Mike worked with surgeons, cardiologists, radiologists, oncologists and neurologists in developing and taking new products to market.

M. Andrew Wade

 Mr. M. Andrew Wade is appointed as the Principal Financial Officer, Principal Accounting Officer of AtriCure Inc. Mr. Wade has served the Company for approximately five years in various financial and accounting functions and during that time has been assisting the Company with the preparation and filing of its periodic reports.

Andrew Lux

 Dr. Andrew L. Lux, Ph.D., is Chief Operating Officer, Vice President of AtriCure, Inc., since January 16, 2012. Since 2010, Dr. Lux served as the Senior Vice President of Manufacturing and Operations for IntriMed Technologies, a start-up business focused on contract manufacturing of implantable medical devices. From 2008 to 2010, Dr. Lux was the Vice President of Research and Development, Operations and Service for WaterHealth International, Inc., a business focused on the water purification/disinfections markets. From 2006 to 2008, Dr. Lux was the General Manager for Medtronic, Inc.’s spinal division in Warsaw, Indiana, where he was responsible for the United States based manufacturing organization providing spinal implant and orthopedic instrumentation products. Prior to 2006, Dr. Lux served in a variety of executive capacities for medical device organizations including Baxter Healthcare, Inc., Medtronic, Inc. (Cardiac Surgery Division), Johnson & Johnson and General Electric Company.

Patricia Kennedy

 Ms. Patricia J. Kennedy has been Vice President, General Manager - International of AtriCure, Inc., since October 2011, having previously served as the Vice President, International Sales from 2009 to 2011 and as the Director of Market Development, Europe from 2008 to 2009. From 2001 through 2008, Ms. Kennedy held various executive level positions with Stereotaxis, Inc., a manufacturer and marketer of cardiology instrument controls systems to enhance the treatment of coronary artery disease and arrhythmias, including Worldwide Vice President, Clinical Services and Vice President Sales and Marketing, Europe. Prior thereto, Ms. Kennedy held various sales and marketing positions in the medical device industry, including positions with EP Medsystems, Inc. and EP Technologies, Inc., a division of Boston Scientific Corporation. Ms. Kennedy, who is a Registered Nurse, received her Bachelor of Science Degree in Marketing from the University of North Florida and an Associates of Science Degree in Technical Nursing from Florida Junior College.

Michael Rogge

 Mr. Michael Rogge has been appointed as Vice President - Marketing of AtriCure Inc. Mike has over 22 years of medical device experience, the past seven with AtriCure building partnerships with Key Opinion Leaders (KOLs) and customer-driven product development initiatives to drive revenue growth. Prior to joining AtriCure, Mr. Rogge held positions at Ethicon Endo-Surgery, a Johnson & Johnson Company, Hill-Rom, and Baxter International.

Stewart Strong

 Mr. Stewart W. Strong is Vice President - Global Marketing of AtriCure Inc., since April 2011, having previously served as the Vice President United States Sales from June 2007 to April 2011 and also in the positions of Vice President, Eastern United States Sales, Northeast Area Sales Director and Regional Sales Manager since joining AtriCure in October 2003. Mr. Strong has over 10 years of cardiac and general surgery sales experience. Prior to joining AtriCure, Mr. Strong held sales positions with the Heart Valve Division of Medtronic, Inc. and Johnson and Johnson’s Ethicon Endo-Surgery division. Mr. Strong received his B.A. from the University of Connecticut.

James Lucky

 Mr. James L. Lucky is Vice President - Regulatory Affairs and Quality Systems of AtriCure Inc., since February 2012, having previously served since January 2004 in various roles including Vice President Regulatory Affairs and Quality Assurance, as well as the Vice President, Quality Assurance and Healthcare Compliance. From 1997 to 2004, Mr. Lucky served as Vice President of Quality Assurance and Regulatory Affairs for the medical segment of Teleflex, Inc., a publicly-held designer and manufacturer of specialty engineered devices for various industries. Prior to that position, Mr. Lucky held a number of quality assurance positions in the medical device industry, including at Ethicon Endo-Surgery, Inc., Bristol-Myers Squibb Company and Parker Hannifin Corp. Mr. Lucky received his B.S. from Western Michigan University, his M.S. from North Carolina State University and his Masters in Business Administration from Duke University.

Michael Hooven

 Mr. Michael D. Hooven is a Director of AtriCure Inc., since August 2002. He is one of founders and as a consultant during 2007 and 2009. From August 2002 through December 2006, Mr. Hooven served as Chief Technology Officer and from August 2002 through February 2005 he served as Chairman of the Board. From November 2000 to August 2002, he served as the President and Chief Executive Officer. Mr. Hooven is currently President and Chief Executive Officer of Enable Medical Technologies, LLC, a start-up business focusing on opportunities in minimally invasive surgery. Since 1994 until its acquisition, Mr. Hooven served as Chairman of the Board, and has previously served as President and Chief Executive Officer of Enable Medical Corporation, a developer and manufacturer of surgical instruments that Mr. Hooven co-founded and that AtriCure acquired on August 10, 2005. Mr. Hooven is also a director of BioOhio, a non-profit organization which promotes the acceleration and growth of life science companies in Ohio, and Minimally Invasive Devices LLC, a privately-held medical device company that develops products that facilitate minimally invasive surgery. From 1986 to 1994, Mr. Hooven served as Director of New Product Development at Ethicon Endo-Surgery, Inc., a developer and manufacturer of minimally invasive surgical instruments. In addition, Mr. Hooven has also served in a variety of positions at Cordis Corporation and Siemens Medical of Siemens AG. Mr. Hooven received his B.S. and M.S. from the University of Michigan.

Mark Collar

 Mr. Mark A. Collar is an Independent Director of AtriCure Inc., since February 2008. Mr. Collar retired in 2008 as an executive from the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative and assumed roles of progressive responsibility within their Health and Personal Care, Beauty Care, New Business Development and Personal Health Care products divisions. Mr. Collar joined Procter and Gamble’s Pharmaceuticals division in 1994 and was named President of Global Pharmaceuticals in 2002. Mr. Collar is currently a venture partner at Triathlon Medical Ventures, a Midwest-based life science venture capital firm, and a director of First Financial Bancorp, a publicly-held bank holding company, in addition to several philanthropic positions. Mr. Collar received his B.S. from Northern Illinois University.

Donald Harrison

 Dr. Donald C. Harrison, M.D., is an Independent Director of AtriCure Inc., since November 2000. Since 2004, Dr. Harrison has served as a Managing Partner of Charter Life Sciences, L.P., a venture capital investment firm. He also serves as a director of several public and private companies, including Kendle International, a publicly-held clinical research company, EnteroMedics, Inc., a publicly-held developer of medical devices for the treatment of obesity and gastrointestinal disorders, Sidis Technologies, Inc., a privately-held information technology services company, CoRepair, Inc., a privately-held heart failure company, Ischemia Care LLC, a privately-held company that performs genetic testing for stroke, and Minimally Invasive Devices LLC, a privately-held medical device company that develops products that facilitate minimally invasive surgery. From 1986 to 2003, Dr. Harrison was the Senior Vice President and Provost for Health Affairs at the University of Cincinnati. In this capacity, he served as the Chief Executive Officer of the Medical Center. Dr. Harrison has previously served as a director of various publicly-held companies, including EP Technology, Inc., Novoste Corporation, InControl, Inc. and SciMed, Inc. From 2000 to 2003, Dr. Harrison served as a director of Enable Medical Corporation, a developer and manufacturer of surgical instruments that AtriCure acquired on August 10, 2005. From 1968 to 1986, Dr. Harrison served as co-director of the Falk Cardiovascular Research Center in Stanford, California, Professor of Medicine and William G. Irwin Professor of Cardiology at Stanford University School of Medicine and Chief of Cardiology at Stanford University Hospital. Dr. Harrison received his B.S. from Birmingham Southern College and his M.D. from the University of Alabama College of Medicine.

Elizabeth Krell

 Dr. Elizabeth D. Krell, Ph.D., is an Independent Director of AtriCure Inc., since June 2006. Dr. Krell is currently a private consultant on matters pertaining to FDA-regulated products, as well as FDA policies and procedures. From 2003 to 2004, she served as the Executive Vice President for Technology and Regulatory Affairs at the Advanced Medical Technology Association (AdvaMed), the trade association for medical device manufacturers. From 1975 to 2001, she served in the FDA, starting as a bench researcher and ending in the FDA’s top science job as the Acting Senior Advisor for Science, advising the Commissioner and other top FDA officials on science and science management. Dr. Krell served from 1990 to 2001 as the Deputy Director for Science, in the FDA’s Center for Devices and Radiological Health (CDRH). In this position she provided executive leadership in the development of programs to assure the safety and effectiveness of medical devices and diagnostic products, and the reduction of population exposure to radiation emitted from medical, industrial and consumer products. Previously, she directed CDRH’s science and engineering labs. Dr. Krell received her B.A. from S.U.N.Y. Binghamton and her Ph.D. from Georgetown University.

Mark Lanning

 Mr. Mark R. Lanning, C.P.A., is an Independent Director AtriCure Inc., since February 2006. Mr. Lanning currently serves as Vice President, Investor Relations of Hillenbrand, Inc., a diversified leader in the funeral services and materials handling industries. Prior to joining Hillenbrand in 1988, Mr. Lanning spent twelve years in various accounting positions with Ernst & Whinney (now Ernst & Young). Mr. Lanning, a Certified Public Accountant, also currently serves as a member of the Council of the American Institute of CPAs and is a past Chairman of the Indiana CPA Society. Mr. Lanning received his B.S. in Accounting from Ball State University.

Karen Robards

 Ms.Karen P. Robards is an Independent Director of AtriCure Inc., since November 2000. Since 1987, Ms. Robards has been a partner of Robards & Company, LLC, a financial advisory firm. From 1976 to 1987, Ms. Robards was an investment banker at Morgan Stanley where she headed its healthcare investment banking activities. Ms. Robards served as a director of Enable Medical Corporation from 1996 to 2005, a developer and manufacturer of surgical instruments, which acquired on August 10, 2005. From 2007 to 2010, Ms. Robards also served as a director of Care Investment Trust, a publicly-held real estate investment trust focusing on investment opportunities in the healthcare industry. Ms. Robards currently serves as Vice Chair of the Board and Chair of the Audit Committee of BlackRock Closed-End Funds. Ms. Robards is a founder and director of the Cooke Center for Learning & Development, a not-for-profit educational organization in New York City. Ms. Robards received her B.A. from Smith College and her M.B.A. from Harvard Business School.

Robert White

 Mr. Robert S. White is appointed as Independent Director of AtriCure, Inc. Mr. White is a veteran in the medical technology industry with over 25 years of experience in commercial expansion, operations and sales. He is currently President and CEO of TYRX, a privately-held company, which commercializes innovative, implantable combination drug and device products focused on infection control, including the AIGISRx® Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs). During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company among others. Mr. White holds a MBA from Cornell University and a BS in Aerospace Engineering from the University of Missouri-Rolla.

Options Compensation

Name Options Value

Richard Johnston

 0 0

Michael Carrel

 0 0

M. Andrew Wade

 0 0

Andrew Lux

 0 0

Patricia Kennedy

 8,750 113,537

Michael Rogge

 0 0

Stewart Strong

 0 0

James Lucky

 36,051 188,218

Michael Hooven

 92,104 945,251

Mark Collar

 0 0

Donald Harrison

 0 0

Elizabeth Krell

 0 0

Mark Lanning

 0 0

Karen Robards

 0 0

Robert White

 0 0

Insider Trading

Name Shares Traded Price

LUCKY JAMES L

 616 $8.22

LUCKY JAMES L

 4,000 $8.22

LUCKY JAMES L

 13,949 $6.34

LUCKY JAMES L

 31,500 $8.13

LUCKY JAMES L

 31,500 $5.60

LUCKY JAMES L

 9,473 $1.52

LUCKY JAMES L

 13,949 $8.13

KENNEDY PATRICIA J

 546 $8.49

WADE M ANDREW

 180 $8.49

LUCKY JAMES L

 851 $8.49

LUCKY JAMES L

 1,136 $8.31

KENNEDY PATRICIA J

 683 $8.16

LUCKY JAMES L

 835 $8.16

LUCKY JAMES L

 358 $5.87

WADE M ANDREW

 281 $5.87

LUCKY JAMES L

 2,500 $0.00

LUX ANDREW L

 10,000 $0.00

WADE M ANDREW

 15,000 $0.00

KENNEDY PATRICIA J

 15,000 $0.00

DISCOVERY GROUP I L L C

 10,000 $6.53

DISCOVERY GROUP I L L C

 19,934 $6.36

DISCOVERY GROUP I L L C

 13,500 $6.13

DISCOVERY GROUP I L L C

 19,800 $6.11

DISCOVERY GROUP I L L C

 6,035 $6.10

DISCOVERY GROUP I L L C

 17,300 $6.13
» Full list on Insider Trading
Search Stocks